Skip to main content
We support all people, families and caregivers living with rare diseases, this Rare Disease Day and every day
Lubner brings 25 years of financial and operational experience in the life sciences industry WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Dyne’s Board of Directors. “We are pleased to welcome David to the Board. He is a seasoned life sciences leader with experience spanning strategy, finance, capital markets, M&A and operations including a strong track record in rare disease,” said Jason P. Rhodes, executive chairman of Dyne’s Board of Directors and partner at Atlas Venture. “I am excited to join Dyne as the company develops therapeutics for patients with myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and other serious muscle diseases based on their pioneering FORCE™ platform,” said Lubner. “I look forward to working closely with the Board and leadership team to execute our growth and capital strategies.” “On behalf of Dyne’s team, I am thrilled to welcome David to the Board,” said Joshua Brumm, president and chief executive officer of Dyne. “We look forward to his contributions as we build the leading muscle disease company and rapidly advance our programs toward the clinic.” Lubner serves as executive vice president and chief financial officer of Ra Pharma, acquired by UCB in April 2020. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition to Dyne’s Board of Directors, he previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019. Lubner is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit, and follow us on Twitter and LinkedIn. Media Contact  Ten Bridge Communications Stephanie Simon, (617) 581-9333